Galizia Gennaro, Gemei Marica, Del Vecchio Luigi, Zamboli Anna, Di Noto Rosa, Mirabelli Peppino, Salvatore Francesco, Castellano Paolo, Orditura Michele, De Vita Ferdinando, Pinto Margherita, Pignatelli Carlo, Lieto Eva
Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery F. Magrassi-A. Lanzara, Second University of Naples School of Medicine, c/o II Policlinico, Edificio 17, 5 Via Pansini, 80131 Naples, Italy.
Arch Surg. 2012 Jan;147(1):18-24. doi: 10.1001/archsurg.2011.795.
Because of some inconsistencies in the traditional model of human colorectal carcinogenesis, the cancer stem cell (CSC) model was recently proposed, in which tumor results from neoplastic transformation of stem cells, which become CSCs. Identification of CSCs by expression of surface antigens remains a critical issue because no biomarker has been shown to be completely reliable. CD133 and CD44 are commonly used as CSC markers, and correlation of their expression with colorectal cancer (CRC) clinicopathological features and outcomes may be useful.
Pilot study.
University hospital.
Thirty-six consecutive patients with CRC. CD133 and CD44 expression (alone or combined) was determined in nontumor cells and in tumor cells by flow cytometry, which identified viable cells only.
Correlation of CD133 and CD44 expression with each other, with other prognostic indicators, and with disease-free survival.
CD133 and CD44 expression was significantly higher in tumor cells than in nontumor cells, and expression of one did not necessarily correlate with expression of the other. CD133 or CD44 expression alone was variable, while combined CD133/CD44 expression identified a small subset of cells positive for CRC. CD133 or CD44 overexpression was not associated with CRC recurrence; only high frequencies of CD133(+)/CD44(+) cells were a strong indicator of worse disease-free survival and an independent risk factor for CRC recurrence.
Evaluation of combined CD133/CD44 expression could be useful to identify putative colorectal CSCs and tumors with a poor prognosis.
由于传统的人类结直肠癌发生模型存在一些不一致之处，最近提出了癌症干细胞（CSC）模型，其中肿瘤是由干细胞的肿瘤转化产生的，这些干细胞成为CSC。通过表面抗原的表达来鉴定CSC仍然是一个关键问题，因为尚未证明有生物标志物是完全可靠的。CD133和CD44通常用作CSC标志物，它们的表达与结直肠癌（CRC）临床病理特征和预后的相关性可能是有用的。
初步研究。
大学医院。
36例连续的CRC患者。通过仅识别活细胞的流式细胞术测定非肿瘤细胞和肿瘤细胞中CD133和CD44的表达（单独或联合）。
CD133和CD44表达之间的相关性、与其他预后指标的相关性以及与无病生存期的相关性。
肿瘤细胞中CD133和CD44的表达明显高于非肿瘤细胞，且一种的表达不一定与另一种的表达相关。单独的CD133或CD44表达是可变的，而联合的CD133/CD44表达可识别出一小部分CRC阳性细胞。CD133或CD44的过表达与CRC复发无关；只有高频率的CD133(+)/CD44(+)细胞是无病生存期较差的有力指标和CRC复发的独立危险因素。
评估联合的CD133/CD44表达可能有助于识别假定的结直肠CSC和预后不良的肿瘤。
